Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
Journal of Medicinal Chemistry · 26.01.2023 · 66 (2) · 1157-1171
DOI: 10.1021/acs.jmedchem.2c01521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.01.2023. Verfasst von Mark E Layton und 18 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. Hauptthemen laut MEDLINE: Phosphodiesterase Inhibitors, Schizophrenia. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme.
Abstract (Originalsprache)
PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional striatal activity with schizophrenia, PDE10A inhibition represents a potentially novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen with earlier compounds and resulted in the invention of compound 18 (MK-8189), which is currently in Phase 2b clinical development for the treatment of schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
- Neuroscience, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
- Structural Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
- In Vivo Pharmacology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
- Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
- Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
ORCID-Profile: Mark E Layton, William D Shipe, Izzat Raheem, Georgia B McGaughey, Jason M Uslaner
Förderung
- Merck Sharp and Dohme
Zitieren
APA
Layton, M. E., Kern, J. C., Hartingh, T. J., Shipe, W. D., Raheem, I., Kandebo, M., Hayes, R. P., Huszar, S., Eddins, D., Ma, B., Fuerst, J., Wollenberg, G. K., Li, J., Fritzen, J., McGaughey, G. B., Uslaner, J. M., Smith, S. M., Coleman, P. J., & Cox, C. D. (2023). Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 66(2), 1157-1171. https://doi.org/10.1021/acs.jmedchem.2c01521
Vancouver
Layton ME, Kern JC, Hartingh TJ, Shipe WD, Raheem I, Kandebo M, et al. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of Medicinal Chemistry. 2023;66(2):1157-1171. doi:10.1021/acs.jmedchem.2c01521
BibTeX
@article{Layton2023,
author = {Layton, Mark E and Kern, Jeffrey C and Hartingh, Timothy J and Shipe, William D and Raheem, Izzat and Kandebo, Monika and Hayes, Robert P and Huszar, Sarah and Eddins, Donnie and Ma, Bennett and Fuerst, Joy and Wollenberg, Gordon K and Li, Jing and Fritzen, Jeff and McGaughey, Georgia B and Uslaner, Jason M and Smith, Sean M and Coleman, Paul J and Cox, Christopher D},
title = {Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {2},
pages = {1157--1171},
doi = {10.1021/acs.jmedchem.2c01521}
}
EUVIMED